Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections – Pipeline Review, H1 2017, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.
Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 3, 2, 7 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Discovery stages comprises 1, 1, 1 and 2 molecules, respectively.
Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioClonetics Immunotherapeutics Inc
ContraFect Corp
Daiichi Sankyo Company Ltd
GlaxoSmithKline Plc
Green Cross Corp
Ilyang Pharmaceutical Co Ltd
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Protein Sciences Corp
Romark Laboratories LC
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
Toyama Chemical Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
Zydus Cadila Healthcare Ltd
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenzavirus B Infections – Overview
Influenzavirus B Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenzavirus B Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenzavirus B Infections – Companies Involved in Therapeutics Development
AbbVie Inc
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioClonetics Immunotherapeutics Inc
ContraFect Corp
Daiichi Sankyo Company Ltd
GlaxoSmithKline Plc
Green Cross Corp
Ilyang Pharmaceutical Co Ltd
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Protein Sciences Corp
Romark Laboratories LC
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
Toyama Chemical Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
Zydus Cadila Healthcare Ltd
Influenzavirus B Infections – Drug Profiles
AL-18 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-0205 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-403 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-404 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
favipiravir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluad (quadrivalent) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FluGEM – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3106A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza (split virion, tetravalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [serotype B] vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [serotypes A, B] (virus like particle) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/victoria+ B/yamagata] (quadrivalent, split virion) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1400 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
laninamivir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Influenza B Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Influenza B Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-607 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide CR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-033188 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VR-736 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXABYW-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zanamivir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zanamivir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenzavirus B Infections – Dormant Projects
Influenzavirus B Infections – Discontinued Products
Influenzavirus B Infections – Product Development Milestones
Featured News & Press Releases
Mar 06, 2017: TSRL Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza
Dec 01, 2016: Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released
Aug 29, 2016: Seqirus receives FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
Aug 29, 2016: Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza
Aug 26, 2016: Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg
Aug 25, 2016: VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccine Fluad in Austria
Jun 23, 2016: New Four-Strain Influenza Vaccine, VaxigripTetra, regulatory dossier from Sanofi Pasteur now approved in Europe
Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
Feb 12, 2016: Protein Sciences and UNIGEN Reach Agreement to Source Flublok Influenza Vaccine from Japan
Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial
Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections
May 12, 2015: Kineta Presents Data On Novel Antiviral Compounds Which Inhibit Broad Spectrum of Respiratory Diseases At International Antiviral Conference
Aug 01, 2014: Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate
May 08, 2014: Biota Provides Update on BARDA Contract for Laninamivir Octanoate
Dec 20, 2013: Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Influenzavirus B Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Influenzavirus B Infections – Pipeline by AbbVie Inc, H1 2017
Influenzavirus B Infections – Pipeline by Altravax Inc, H1 2017
Influenzavirus B Infections – Pipeline by Amarillo Biosciences Inc, H1 2017
Influenzavirus B Infections – Pipeline by Aphios Corp, H1 2017
Influenzavirus B Infections – Pipeline by BioClonetics Immunotherapeutics Inc, H1 2017
Influenzavirus B Infections – Pipeline by ContraFect Corp, H1 2017
Influenzavirus B Infections – Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Influenzavirus B Infections – Pipeline by GlaxoSmithKline Plc, H1 2017
Influenzavirus B Infections – Pipeline by Green Cross Corp, H1 2017
Influenzavirus B Infections – Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2017
Influenzavirus B Infections – Pipeline by Kineta Inc, H1 2017
Influenzavirus B Infections – Pipeline by Medicago Inc, H1 2017
Influenzavirus B Infections – Pipeline by MedImmune LLC, H1 2017
Influenzavirus B Infections – Pipeline by Mucosis BV, H1 2017
Influenzavirus B Infections – Pipeline by Novavax Inc, H1 2017
Influenzavirus B Infections – Pipeline by Protein Sciences Corp, H1 2017
Influenzavirus B Infections – Pipeline by Romark Laboratories LC, H1 2017
Influenzavirus B Infections – Pipeline by Sanofi Pasteur SA, H1 2017
Influenzavirus B Infections – Pipeline by Shionogi & Co Ltd, H1 2017
Influenzavirus B Infections – Pipeline by SK Chemicals Co Ltd, H1 2017
Influenzavirus B Infections – Pipeline by Toyama Chemical Co Ltd, H1 2017
Influenzavirus B Infections – Pipeline by TSRL Inc, H1 2017
Influenzavirus B Infections – Pipeline by Vaxart Inc, H1 2017
Influenzavirus B Infections – Pipeline by Vectura Group Plc, H1 2017
Influenzavirus B Infections – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Influenzavirus B Infections – Dormant Projects, H1 2017
Influenzavirus B Infections – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Influenzavirus B Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
